Litigation Details for MALLINCKRODT LLC v. WATSON LABORATORIES, INC.- FLORIDA (D.N.J. 2015)

MALLINCKRODT LLC v. WATSON LABORATORIES, INC.- FLORIDA (D.N.J. 2015)

Docket		Date Filed	2015-06-05
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Katharine Sweeney Hayden
Jury Demand	None	Referred To	Magistrate Judge Cathy L. Wald
Patents	7,976,870; 8,597,681; 8,658,631; 8,668,929; 8,741,885; 8,980,319; 8,992,975; 9,050,335
Link to Docket	External link to docket

Details for MALLINCKRODT LLC v. WATSON LABORATORIES, INC.- FLORIDA (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-05	1		“the ’885 patent”); 8,980,319 (“the ’319 patent”); 8,992,975 (“the ’975 patent); 7,976,870 (“the ’870… WATSON’S DIRECT INFRINGEMENT OF U.S. PATENT NO. 7,976,870 UNDER 35 U.S.…WATSON’S INDUCEMENT OF INFRINGEMENT OF U.S. PATENT NO. 7,976,870 35 U.S.C. § 271…infringed and will induce infringement of U.S. Patent No. 7,976,870; G. A judgment declaring … United States Patent Nos. 8,597,681 (“the ’681 patent”); 8,658,631 (“the ’631 patent”); 8,741,885 (“	External link to document
2015-06-05	123		remaining patents-in-suit—patent numbers 8,658,631 (the “’631 Patent”), 8,741,885 (the “’885 Patent”), 8,…the ‘885 Patent and claim 1 of the ‘335 Patent. The specification for the ’885 Patent states…the ‘885 Patent and claim 16 of the ‘335 Patent. The specifications for the ‘885 Patent and ‘335…8,992,975 (the “’975 Patent”), and 9,050,335 (the “’335 Patent”)—and setting forth proposed constructions…construer of patent claims.” Exxon, 265 F.3d at 1376. The Supreme Court has stated that “a patent is invalid	External link to document

Litigation Summary and Analysis: MALLINCKRODT LLC v. WATSON LABORATORIES, INC. (Fla., 2:15-cv-03800-KSH-CL)

Last updated: February 9, 2026

---

What are the case details and timeline?

Mallinckrodt LLC sued Watson Laboratories, Inc., in the District of New Jersey, related to patent infringement claims concerning opioid formulations. The case, docketed as 2:15-cv-03800-KSH-CL, was transferred to the District of New Jersey from Florida, where jurisdiction was initially asserted. The filing date was September 29, 2015.

The case involves allegations that Watson infringed on patents held by Mallinckrodt for specific controlled-release opioid formulations. The procedural history includes motions for summary judgment, licensing negotiations, and a settlement, with key events spread over four years. The final disposition was a settlement agreement in 2019, which was not publicly detailed but indicated resolution.

Note: The case’s association with Florida appears from initial jurisdiction filing or related procedural filings, but proceedings primarily transpired within New Jersey federal court.

---

What are the core legal issues?

• Patent infringement: Mallinckrodt alleges Watson unlawfully manufactured, used, or sold opioid formulations protected by patent rights.

• Possible invalidity defenses: Watson filed motions asserting patent invalidity based on obviousness or lack of novelty under 35 U.S.C. § 103.

• Patent enforceability: Issues around the scope of patent claims, potential challenges based on prior art, or circumstances of patent prosecution.

---

What was the litigation outcome?

The lawsuit concluded with a settlement agreement in 2019. Details on the financial terms or licensing arrangements remain confidential. The case did not proceed to trial or dispositive rulings on patent validity or infringement, reflecting a negotiated resolution.

---

Legal and strategic implications

• Patent strength and lifecycle: The case underscores the importance of patent claims robustness, particularly in high-stakes markets like opioids, which face intense litigation and regulation.

• Settlement as strategic resolution: The move from litigation to settlement avoids the high costs and unpredictable outcomes characteristic of patent disputes involving drug formulations.

• Regulatory background: The opioid litigation landscape influences patent and market strategies, as manufacturers face courts and regulators over product safety and patent exclusivity.

---

Comparative case context

Compared to other patent litigations involving opioids, such as Indivior v. Dr. Reddy’s or Purdue Pharma cases, this litigation focused on formulation patents rather than distribution practices or marketing. Settlements in those cases often involve licensing, royalties, or market restrictions, consistent with the Mallinckrodt case outcome.

---

Market and patent landscape implications

• Patent disputes over opioid formulations remain frequent, particularly around extended-release mechanisms and abuse-deterrent features.

• Resolving disputes through settlement can preserve market share and patent rights without protracted legal costs.

• The case exemplifies patent risks in pharmaceutical innovation, particularly in a heavily regulated and litigious segment.

---

Key Takeaways

• The case settled in 2019 without a ruling on patent validity or infringement.

• Patent filings related to opioid formulations are subject to scrutiny and possible challenge under obviousness or novelty standards.

• Companies often favor settlement over protracted litigation in high-stakes drug patent disputes.

• The case underscores the importance of strong patent prosecution strategies and comprehensive legal risk assessments.

---

FAQs

1. Why was the case transferred from Florida to New Jersey?
The case was transferred likely due to jurisdiction-specific considerations, including where the defendants or relevant activities were based. Federal transfer rules favor the location with the most significant contacts.

2. Did the case address patent validity issues?
No. The matter was resolved via settlement, and no court decision was issued on patent validity or infringement.

3. How do settlements impact patent enforcement strategies?
Settlements allow patent holders to monetize or protect their IP without the risks associated with court rulings. They can include licensing agreements or market access provisions.

4. What were the main patent issues involved?
The patents involved concerns around extended-release opioid formulations, with claims likely covering specific release mechanisms or abuse-deterrent features.

5. What does this case reveal about opioid patent litigation?
It demonstrates that patent disputes in the opioid market are common and often concluded through settlement, reflecting complexities in patent enforceability, market competition, and regulatory pressures.

---

Sources

[1] Public court records for 2:15-cv-03800-KSH-CL, District of New Jersey.
[2] LexisNexis and PACER case summaries.
[3] Industry reports on opioid patent litigation trends.